Umeå universitets logga

umu.sePublikationer
Ändra sökning
Avgränsa sökresultatet
12 1 - 50 av 98
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Träffar per sida
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sortering
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
  • Standard (Relevans)
  • Författare A-Ö
  • Författare Ö-A
  • Titel A-Ö
  • Titel Ö-A
  • Publikationstyp A-Ö
  • Publikationstyp Ö-A
  • Äldst först
  • Nyast först
  • Skapad (Äldst först)
  • Skapad (Nyast först)
  • Senast uppdaterad (Äldst först)
  • Senast uppdaterad (Nyast först)
  • Disputationsdatum (tidigaste först)
  • Disputationsdatum (senaste först)
Markera
Maxantalet träffar du kan exportera från sökgränssnittet är 250. Vid större uttag använd dig av utsökningar.
  • 1. Bakris, George L
    et al.
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Black, Henry R
    Krum, Henry
    Linas, Stuart
    Linseman, Jennifer V
    Arterburn, Sarah
    Sager, Philip
    Weber, Michael
    Divergent results using clinic and ambulatory blood pressures report of a darusentan-resistant hypertension trial2010Ingår i: Hypertension, ISSN 0194-911X, E-ISSN 1524-4563, Vol. 56, nr 5, s. 824-830Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing therapies will help achieve blood pressure (BP) goals in more resistant hypertension patients. In the current trial, 849 patients with resistant hypertension receiving ≥3 antihypertensive drugs, including a diuretic, at optimized doses were randomized to the selective endothelin A receptor antagonist darusentan, placebo, or the central α-2 agonist guanfacine. The coprimary end points of the study were changes from baseline to week 14 in trough, sitting systolic BP, and diastolic BP measured in the clinic. Decreases from baseline to week 14 in systolic BP for darusentan (−15±14 mm Hg) were greater than for guanfacine (−12±13 mm Hg; P<0.05) but not greater than placebo (−14±14 mm Hg). Darusentan, however, reduced mean 24-hour systolic BP (−9±12 mm Hg) more than placebo (−2±12 mm Hg) or guanfacine (−4±12 mm Hg) after 14 weeks of treatment (P<0.001 for each comparison). The most frequent adverse event associated with darusentan was fluid retention/edema at 28% versus 12% in each of the other groups. More patients withdrew because of adverse events on darusentan as compared with placebo or guanfacine. We conclude that darusentan provided greater reduction in systolic BP in resistant hypertension patients as assessed by ambulatory BP monitoring, in spite of not meeting its coprimary end points. The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies.

  • 2. Bejan-Angoulvant, Theodora
    et al.
    Saadatian-Elahi, Mitra
    Wright, James M
    Schron, Eleanor B
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Fagard, Robert
    Staessen, Jan A
    Gueyffier, François
    Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials.2010Ingår i: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 28, nr 7, s. 1366-1372Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: Results of randomized controlled trials are consistent in showing reduced rates of stroke, heart failure and cardiovascular events in very old patients treated with antihypertensive drugs. However, inconsistencies exist with regard to the effect of these drugs on total mortality.

    Methods: We performed a meta-analysis of available data on hypertensive patients 80 years and older by selecting total mortality as the main outcome. Secondary outcomes were coronary events, stroke, cardiovascular events, heart failure and cause-specific mortality. The common relative risk (RR) of active treatment versus placebo or no treatment was assessed using a random-effect model. Linear meta-regression was performed to explore the relationship between intensity of antihypertensive therapy and blood pressure (BP) reduction and the log-transformed value of total mortality odds ratios (ORs).

    Results: The overall RR for total mortality was 1.06 (95% confidence interval 0.89–1.25), with significant heterogeneity between hypertension in the very elderly trial (HYVET) and the other trials. This heterogeneity was not explained by differences in the follow-up duration between trials. The meta-regression suggested that a reduction in mortality was achieved in trials with the least BP reductions and the lowest intensity of therapy. Antihypertensive therapy significantly reduced (P < 0.001) the risk of stroke (35%), cardiovascular events (27%) and heart failure (50%). Cause-specific mortality was not different between treated and untreated patients.

    Conclusion: Treating hypertension in very old patients reduces stroke and heart failure with no effect on total mortality. The most reasonable strategy is the one associated with significant mortality reduction; thiazides as first-line drugs with a maximum of two drugs.

  • 3. Black, HR
    et al.
    Bakris, GL
    Weber, MA
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Darusentan for resistant hypertension2006Ingår i: Journal of Hypertension, Vol. 24, s. 95-96Artikel i tidskrift (Övrigt vetenskapligt)
  • 4.
    Brunström, Mattias
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Dahlström, John
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Lindholm, Lars Hjalmar
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Lönnberg, Göran
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Epidemiologi och global hälsa.
    Hallström, Sara
    Norberg, Margareta
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Epidemiologi och global hälsa.
    Nyström, Lennarth
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Epidemiologi och global hälsa.
    Persson, Mats
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Weinehall, Lars
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Epidemiologi och global hälsa.
    Carlberg, Bo
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    From efficacy in trials to effectiveness in clinical practice: The Swedish Stroke Prevention Study2016Ingår i: Blood Pressure, ISSN 0803-7051, E-ISSN 1651-1999, Vol. 25, nr 4, s. 206-211Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Blood pressure treatment has shown great efficacy in reducing cardiovascular events in randomized controlled trials. If this is effective in reducing cardiovascular disease in the general population, is less studied. Between 2001 and 2009 we performed an intervention to improve blood pressure control in the county of Vasterbotten, using Sodermanland County as a control. The intervention was directed towards primary care physicians and included lectures on blood pressure treatment, a computerized decision support system with treatment recommendations, and yearly feed back on hypertension control. Each county had approximately 255000 inhabitants. Differences in age and incidence of cardiovascular disease were small. During follow-up, more than 400000 patients had their blood pressure recorded. The mean number of measurements was eight per patient, yielding a total of 3.4 million blood pressure recordings. The effect of the intervention will be estimated combining the blood pressure data collected from the electronic medical records, with data on stroke, myocardial infarction and mortality from Swedish health registers. Additional variables, from health registers and Statistics Sweden, will be collected to address for confounders. The blood pressure data collected within this study will be an important asset for future epidemiological studies within the field of hypertension.

  • 5.
    Brunström, Mattias
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Avdelningen för medicin.
    Ng, Nawi
    Umeå universitet, Medicinska fakulteten, Institutionen för epidemiologi och global hälsa. School of Public Health and Community Medicine, Institution of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
    Dahlström, John
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Avdelningen för medicin.
    Lindholm, Lars H.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Norberg, Margareta
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Avdelningen för medicin.
    Nyström, Lennarth
    Umeå universitet, Medicinska fakulteten, Institutionen för epidemiologi och global hälsa.
    Weinehall, Lars
    Umeå universitet, Medicinska fakulteten, Institutionen för epidemiologi och global hälsa.
    Carlberg, Bo
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Avdelningen för medicin.
    Association of education and feedback on hypertension management with risk for stroke and cardiovascular disease2022Ingår i: Blood Pressure, ISSN 0803-7051, E-ISSN 1651-1999, Vol. 31, nr 1, s. 31-39Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    PURPOSE: Education and feedback on hypertension management has been associated with improved hypertension control. This study aimed to assess the effectiveness of such interventions to reduce the risk of stroke and cardiovascular events. MATERIALS AND METHODS: Individuals ≥18 years with a blood pressure (BP) recording in Västerbotten or Södermanland County during the study period 2001 to 2009 were included in 108 serial cohort studies, each with 24 months follow-up. The primary outcome was risk of first-ever stroke in Västerbotten County (intervention) compared with Södermanland County (control). Secondary outcomes were first-ever major adverse cardiovascular event (MACE), myocardial infarction, and heart failure, as well as all-cause and cardiovascular mortality. All outcomes were analysed using time-to-event data included in a Cox proportional hazards model adjusted for age, sex, hypertension, diabetes, coronary artery disease, atrial fibrillation, systolic BP at inclusion, marital status, and disposable income. RESULTS: A total of 121 365 individuals (mean [SD] age at inclusion 61.7 [16.3] years; 59.9% female; mean inclusion BP 142.3/82.6 mmHg) in the intervention county were compared to 131 924 individuals (63.6 [16.2] years; 61.2% female; 144.1/81.1 mmHg) in the control county. A first-ever stroke occurred in 2 823 (2.3%) individuals in the intervention county, and 3 584 (2.7%) individuals in the control county (adjusted hazard ratio 0.96, 95% CI 0.90 to 1.03). No differences were observed for MACE, myocardial infarction or heart failure, whereas all-cause mortality (HR 0.91, 95% CI 0.87 to 0.95) and cardiovascular mortality (HR 0.91, 95% CI 0.85 to 0.98) were lower in the intervention county. CONCLUSIONS: This study does not support an association between education and feedback on hypertension management to primary care physicians and the risk for stroke or cardiovascular outcomes. The observed differences for mortality outcomes should be interpreted with caution.

    Ladda ner fulltext (pdf)
    fulltext
  • 6.
    Carlberg, Bo
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.
    Frishman, William H.
    Department of Medicine, New York Medical College, Valhalla, NY, United States; Westchester Medical Center, Valhalla, NY, United States.
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin.
    β-blockers in hypertension2012Ingår i: Hypertension: a companion to Braunwald's heart disease / [ed] Henry R. Black, Saunders Elsevier, 2012, 2, s. 172-178Kapitel i bok, del av antologi (Refereegranskat)
  • 7.
    Carlberg, Bo
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Lindholm, Lars Hjalmar
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Comment: Stroke and blood-pressure variation: new permutations on an old theme.2010Ingår i: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 375, nr 9718, s. 867-869Artikel i tidskrift (Refereegranskat)
  • 8.
    Carlberg, Bo
    et al.
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Medicin.
    Samuelsson, Ola
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Atenolol in hypertension: is it a wise choice?2004Ingår i: Lancet, ISSN 1474-547X, Vol. 364, nr 9446, s. 1684-9Artikel i tidskrift (Refereegranskat)
  • 9.
    Carlberg, Bo
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Samuelsson, Ola
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Finns möjligen hela bilden om atenolol hos Kent Forsén?2005Ingår i: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 102, nr 3, s. 151-152Artikel i tidskrift (Övrigt vetenskapligt)
  • 10. Carr, Albert A
    et al.
    Kowey, Peter R
    Devereux, Richard B
    Brenner, Barry M
    Dahlöf, Björn
    Ibsen, Hans
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Lyle, Paulette A
    Snapinn, Steven M
    Zhang, Zhongxin
    Edelman, Jonathan M
    Shahinfar, Shahnaz
    Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.2005Ingår i: Am J Cardiol, ISSN 0002-9149, Vol. 96, nr 11, s. 1530-6Artikel i tidskrift (Refereegranskat)
  • 11. Cicala, Silvana
    et al.
    de Simone, Giovanni
    Gerdts, Eva
    Dahlöf, Björn
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Kjeldsen, Sverre E
    Devereux, Richard B
    Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan intervention for endpoint reduction in hypertension study2010Ingår i: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 28, nr 6, s. 1134-1140Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Objective: Construction of prognostically relevant endpoints for clinical trials in hypertension has increasingly included coronary revascularization with myocardial infarction (MI) as manifestations of coronary artery disease. However, whether coronary revascularization and MI predict other cardiovascular events similarly is unknown.

     

    Methods: We examined risks of cardiovascular death, all-cause death, and stroke following MI or coronary revascularization in hypertensive patients with left ventricular hypertrophy (LVH) enrolled in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). We studied 9113 patients after excluding those who died within 7 days after MI or underwent coronary revascularization within 24 h after MI.

     

    Results: In multivariate Cox regression adjusting for participating countries, time-varying systolic blood pressure, and Framingham risk score, hazard ratios for cardiovascular death, all-cause death, and stroke were, respectively, 4.5 (P < 0.0001), 2.9 (P < 0.0001), and 1.9 (P = 0.003) in 321 patients with MI as first event. In similar models, coronary revascularization as first event (n = 202) was not associated with increased risks of cardiovascular death, all-cause death, and stroke (P = 0.06–0.86).

     

    Conclusion: During follow-up of hypertensive patients with LVH, occurrence of MI but not coronary revascularization as first cardiovascular event significantly increased risk of subsequent cardiovascular death, all-cause death, and stroke. In view of differences in prognostic implications, when the goal is to have a prognostically relevant composite endpoint for trials in hypertensive patients, caution should be used in combining coronary revascularization with MI.

  • 12. de Simone, G
    et al.
    Wachtell, K
    Palmieri, V
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Body build and risk of cardiovascular events in hypertension: The LIFE study2005Ingår i: Circulation, Vol. 110, nr suppl, s. 771-Artikel i tidskrift (Övrigt vetenskapligt)
  • 13. de Simone, Giovanni
    et al.
    Wachtell, Kristian
    Palmieri, Vittorio
    Hille, Darcy A
    Beevers, Gareth
    Dahlöf, Björn
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Julius, Stevo
    Kjeldsen, Sverre E
    Lederballe-Pedersen, Ole
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Nieminen, Markku S
    Omvik, Per
    Oparil, Suzanne
    Devereux, Richard B
    Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.2005Ingår i: Circulation, ISSN 1524-4539, Vol. 111, nr 15, s. 1924-31Artikel i tidskrift (Refereegranskat)
  • 14. Devereux, Richard B
    et al.
    de Faire, Ulf
    Fyhrquist, Frej
    Harris, Katherine E
    Ibsen, Hans
    Kjeldsen, Sverre E
    Lederballe-Pedersen, Ole
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Nieminen, Markku S
    Omvik, Per
    Oparil, Suzanne
    Wedel, Hans
    Hille, Darcy A
    Dahlöf, Björn
    Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.2007Ingår i: Current Medical Research and Opinion, ISSN 0300-7995, E-ISSN 1473-4877, Vol. 23, nr 2, s. 259-70Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Objective: To compare blood pressure response and antihypertensive medication use visit-by-visit from baseline in patients receiving losartan-based or atenolol-based therapy in the LIFE study.

    Research design: LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy. Systolic and diastolic, pulse, and mean arterial pressures, blood pressure responder rates, distribution of open-label anti hypertensive agents utilized, and the proportion of patients on randomized treatment were determined for each group at each clinic visit over a follow-up period of at least 4 years.

    Results: Overall blood pressure reductions were comparable in the losartan-based and atenolol-based treatment groups. The mean reductions in sifting trough systolic and diastolic blood pressures from baseline to the end of follow-up (or last visit before a primary endpoint event) were 30.2/16.6 mmHg in the losartan group and 29.1/16.8 mmHg in the atenolol group. The time-averaged difference in overall mean arterial pressure was similar between groups. The proportion of patients on individual dose combinations varied visit by visit but was generally comparable between groups. During the entire study, 56% (2579/4605) of losartan-treated patients received at least one dose of the combination of losartan 100 mg plus hydrochlorothiazide 12.5 mg and 51 % of atenolol-treated patients received 100mg of atenolol plus hydrochlorothiazide 12.5 mg at some time during the study.

    Conclusions: Differences in blood pressure or distribution of add-on medications between treatment groups were not evident in the LIFE trial and, thus, cannot account for the observed outcome difference in the primary endpoint of risk reduction of the composite of cardiovascular death, stroke and MI favoring losartan.

  • 15. Eijkelkamp, Wouter B A
    et al.
    Zhang, Zhongxin
    Brenner, Barry M
    Cooper, Mark E
    Devereux, Richard B
    Dahlöf, Björn
    Ibsen, Hans
    Keane, William F
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Olsen, Michael H
    Parving, Hans-Henrik
    Remuzzi, Giuseppe
    Shahinfar, Shahnaz
    Snapinn, Steven M
    Wachtell, Kristian
    de Zeeuw, Dick
    Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.2007Ingår i: Journal of Hypertension, ISSN 0263-6352, Vol. 25, nr 4, s. 871-6Artikel i tidskrift (Refereegranskat)
  • 16. Fagard, R H
    et al.
    Grassi, G
    Hall, J
    Harrap, S
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Schiffrin, E
    Heagerty, T
    International Society of Hypertension Low and Middle Income Countries Committee Review of the Goals of the Committee and of 5 years of ISH activities in Low and Middle Income Countries2010Ingår i: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 28, nr 3, s. 635-636Artikel i tidskrift (Refereegranskat)
  • 17. Fossum, Eigil
    et al.
    Moan, Andreas
    Kjeldsen, Sverre E
    Devereux, Richard B
    Julius, Stevo
    Snapinn, Steven M
    Edelman, Jonathan M
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Kristianson, Krister
    Lederballe-Pedersen, Ole
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Nieminen, Markku S
    Omvik, Per
    Oparil, Suzanne
    Wedel, Hans
    Dahlöf, Björn
    The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.2005Ingår i: J Am Coll Cardiol, ISSN 0735-1097, Vol. 46, nr 5, s. 770-5Artikel i tidskrift (Refereegranskat)
  • 18. Fyhrquist, Frej
    et al.
    Dahlöf, Björn
    Devereux, Richard B
    Kjeldsen, Sverre E
    Julius, Stevo
    Beevers, Gareth
    de Faire, Ulf
    Ibsen, Hans
    Kristianson, Krister
    Lederballe-Pedersen, Ole
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Nieminen, Markku S
    Omvik, Per
    Oparil, Suzanne
    Hille, Darcy A
    Lyle, Paulette A
    Edelman, Jonathan M
    Snapinn, Steven M
    Wedel, Hans
    Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.2005Ingår i: Hypertension, ISSN 1524-4563, Vol. 45, nr 4, s. 580-5Artikel i tidskrift (Refereegranskat)
  • 19.
    Griffin, Simon
    et al.
    Umeå universitet. Cambridge University, Cambridge, UK.
    Lindholm, Lars H.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Spencer, Stuart
    The Lancet, London, UK.
    Framgång för den nationella forskarskolan i allmänmedicin: nu finns förutsättningar för svensk allmänmedicinsk forskning att bli internationellt konkurrenskraftig: [Success for the national research school in general medicine]2017Ingår i: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 114, nr 35-36, artikel-id ER3IArtikel i tidskrift (Övrigt vetenskapligt)
    Abstract [sv]

    De flesta kontakter inom hälso- och sjukvård sker i primärvården, men huvuddelen av medicinsk forskning sker på sjukhus och laboratorier. Att ta fram evidens som är relevant för primärvård förutsätter en kritisk massa av multidisciplinära forskare med förmåga att samarbeta med nationella och internationella forskningscentrum. År 2009 etablerades den nationella forskarskolan i allmänmedicin i Sverige för att svara mot detta behov. Skolan har hitintills medverkat till 31 doktorsavhandlingar och ett flertal internationella forskningssamarbeten. Samverkande multidisciplinära forskningsmiljöer är en framgångsfaktor för att skapa hållbara och internationellt konkurrenskraftiga forskningsprogram i primärvård.

  • 20. Halldin, Mats
    et al.
    Hjemdahl, Paul
    de Faire, Ulf
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Samuelsson, Ola
    [Reply from the SBU about salt and high blood pressure: More controlled long-term trials are required]2004Ingår i: Lakartidningen, ISSN 0023-7205, Vol. 101, nr 51-52, s. 4257-Artikel i tidskrift (Övrigt vetenskapligt)
  • 21.
    Hedblad, B
    et al.
    Lund Univ, Malmö, Sweden .
    Melander, H
    Med Prod Agcy, Uppsala, Sweden .
    de Faire, U
    Karolinska Inst, Stockholm, Sweden .
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Kahan, T
    Karolinska Inst, Stockholm, Sweden .
    Beta blockers reduce left ventricular mass less than other antihypertensive drugs: a systematic review and meta analysis2009Ingår i: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 27, nr Suppl. 4, s. s319-s319Artikel i tidskrift (Refereegranskat)
  • 22. Ibsen, Hans
    et al.
    Wachtell, Kristian
    Olsen, Michael H
    Borch-Johnsen, Knut
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Mogensen, Carl Erik
    Dahlöf, Björn
    Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study.2004Ingår i: Kidney Int Suppl, ISSN 0098-6577, nr 92, s. S56-8Artikel i tidskrift (Refereegranskat)
  • 23. Ibsen, Hans
    et al.
    Wachtell, Kristian
    Olsen, Michael H
    Borch-Johnsen, Knut
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Mogensen, Carl Erik
    Dahlöf, Björn
    Devereux, Richard B
    de Faire, Ulf
    Fyhrquist, Frej
    Julius, Stevo
    Kjeldsen, Sverre E
    Lederballe-Pedersen, Ole
    Nieminen, Markku S
    Omvik, Per
    Oparil, Suzanne
    Wan, Ying
    Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.2004Ingår i: J Hypertens, ISSN 0263-6352, Vol. 22, nr 9, s. 1805-11Artikel i tidskrift (Refereegranskat)
  • 24. Jönsson, Bengt
    et al.
    Carides, George W
    Burke, Thomas A
    Dasbach, Erik J
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Dahlöf, Björn
    Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.2005Ingår i: J Hypertens, ISSN 0263-6352, Vol. 23, nr 7, s. 1425-31Artikel i tidskrift (Refereegranskat)
  • 25. Kizer, Jorge R
    et al.
    Dahlöf, Björn
    Kjeldsen, Sverre E
    Julius, Stevo
    Beevers, Gareth
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Kristianson, Krister
    Lederballe-Pedersen, Ole
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Nieminen, Markku S
    Omvik, Per
    Oparil, Suzanne
    Wedel, Hans
    Wachtell, Kristian
    Edelman, Jonathan M
    Snapinn, Steven M
    Harris, Katherine E
    Devereux, Richard B
    Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.2005Ingår i: Hypertension, ISSN 1524-4563, Vol. 45, nr 1, s. 46-52Artikel i tidskrift (Refereegranskat)
  • 26. Kizer, JR
    et al.
    Hoieggen, A
    Alderman, MH
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: the losartan intervention for endpoint reduction in hypertension.2004Ingår i: Journal of the American College of Cardiology: Suppl, Vol. 43, s. 475A-Artikel i tidskrift (Övrigt vetenskapligt)
  • 27. Kjeldsen, SE
    et al.
    Dahlöf, B
    Devereaux, RB
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Benefits of losartan on preventing stroke in patients with isolated systolic hypertension:: A LIFE substudy2004Ingår i: Journal of the Americal College of Cardiology, Vol. 43, s. 482 A-Artikel i tidskrift (Övrigt vetenskapligt)
  • 28.
    Kjeldsen, Sverre E
    et al.
    University of Oslo, Ullevaal Hospital, Oslo, Norway.
    Devereux, Richard B
    Weill Cornell Medical College, New York, NY, USA.
    Hille, Darcy A
    Merck Research Laboratories, North Wales, PA, USA.
    Lyle, Paulette A
    Merck Research Laboratories, North Wales, PA, USA.
    Dahlöf, Björn
    Sahlgrenska University Hospital/Östra, Göteborg, Sweden.
    Julius, Stevo
    University of Michigan Medical Center, Ann Arbor, MI, USA.
    Edelman, Jonathan M
    Merck Research Laboratories, North Wales, PA, USA.
    Snapinn, Steven M
    Merck Research Laboratories, North Wales, PA, USA.
    de Faire, Ulf
    Karolinska University Hospital, Stockholm, Sweden.
    Fyhrquist, Frej
    Helsinki University Central Hospital, Helsinki, Finland.
    Ibsen, Hans
    Holbaek Hospital, Holbaek, Denmark.
    Lederballe-Pedersen, Ole
    Viborg Hospital, Viborg, Denmark.
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Nieminen, Markku S
    Helsinki University Central Hospital, Helsinki, Finland.
    Omvik, Per
    Haukeland University Hospital, Bergen, Norway.
    Oparil, Suzanne
    University of Alabama Medical Center, Birmingham, AL, USA.
    Wedel, Hans
    Nordic School of Public Health, Göteborg, Sweden.
    Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the losartan inventervention for endpoint reduction in hypertension study2009Ingår i: Blood Pressure, ISSN 0803-7051, E-ISSN 1651-1999, Vol. 18, nr 6, s. 348-361Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Objective. We assessed readily available patient characteristics, including albuminuria (not included in traditional cardiovascular risk scores), as predictors of cardiovascular events in hypertension with left ventricular hypertrophy (LVH) and developed risk algorithms/scores for outcomes.

    Methods. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study compared effects of losartan-based versus atenolol-based therapy on cardiovascular events in 9193 patients with hypertension and LVH. Univariate and multivariate analyses identified baseline variables with significant impact on development of the primary composite endpoint (cardiovascular death, stroke and myocardial infarction) and its components. Multivariate analysis used a Cox regression model with stepwise selection process. Risk scores were developed from coefficients of risk factors from the multivariate analysis, validated internally using naïve and jack-knife procedures, checked for discrimination and calibration, and compared with Framingham coronary heart disease and other risk scores.

    Results. LIFE risk scores showed increasing endpoint rates with increasing quintile (first to fifth quintile, composite endpoint 2.8–26.7%, cardiovascular death 0.5–14.4%, stroke 1.2–11.3%, myocardial infarction 1.4–8.1%) and were confirmed with a jack-knife approach that adjusts for potentially optimistic bias. The Framingham coronary heart disease and other risk scores overestimated risk in lower risk patients and underestimated risk in higher risk patients, except for myocardial infarction.

    Conclusion. A number of patient characteristics predicted cardiovascular events in patients with hypertension and LVH. Risk scores developed from these patient characteristics, including albuminuria, strongly predicted outcomes and may improve risk assessment of patients with hypertension and LVH and planning of clinical trials.

  • 29. Kjeldsen, Sverre E
    et al.
    Lyle, Paulette A
    Kizer, Jorge R
    Dahlöf, Björn
    Devereux, Richard B
    Julius, Stevo
    Beevers, Gareth
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Kristianson, Krister
    Lederballe-Pedersen, Ole
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Nieminen, Markku S
    Omvik, Per
    Oparil, Suzanne
    Snapinn, Steven M
    Harris, Katherine E
    Wedel, Hans
    The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.2005Ingår i: J Clin Hypertens (Greenwich), ISSN 1524-6175, Vol. 7, nr 3, s. 152-8Artikel i tidskrift (Refereegranskat)
  • 30. Kjeldsen, Sverre E
    et al.
    Lyle, Paulette A
    Tershakovec, Andrew M
    Devereux, Richard B
    Oparil, Suzanne
    Dahlöf, Björn
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Kristianson, Krister
    Lederballe-Pedersen, Ole
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Nieminen, Markku S
    Omvik, Per
    Wedel, Hans
    Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.2005Ingår i: Expert Opin Emerg Drugs, ISSN 1744-7623, Vol. 10, nr 4, s. 729-45Artikel i tidskrift (Refereegranskat)
  • 31. Kohler, Stefan
    et al.
    Annerstedt, Kristi Sidney
    Diwan, Vishal
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Epidemiologi och global hälsa.
    Randive, Bharat
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Epidemiologi och global hälsa. Department of Public Health and Environment, R. D. Gardi Medical College, Ujjain, India..
    Vora, Kranti
    De Costa, Ayesha
    Postpartum quality of life in Indian women after vaginal birth and cesarean section: a pilot study using the EQ-5D-5L descriptive system2018Ingår i: BMC Pregnancy and Childbirth, ISSN 1471-2393, E-ISSN 1471-2393, Vol. 18, artikel-id 427Artikel i tidskrift (Refereegranskat)
    Abstract [en]

    Background: There has been little evaluation of the postpartum quality of life (QOL) of women in India and its association with the mode of birth. This study piloted the use of the generic EQ-5D-5L questionnaire to assess postpartum QOL experienced by rural Indian women.

    Methods: A convenience sample of rural women who gave birth in a health facility in Gujarat or Madhya Pradesh was recruited into this pilot study. QOL was measured during three interviews within 30days of birth using the EQ-5D-5L questionnaire. Patient-level quality-adjusted life days (QALDs) were estimated. Multivariate regression was used to adjust for selected baseline characteristics.

    Results: Forty-six women with cesarean section and 178 with vaginal birth from 17 public and private health facilities were studied. Postpartum QOL in both groups improved between interviews 1 and 3. Comparing between vaginal and cesarean births indicated that the vaginal birth group had a higher QOL (0-3 days postpartum: 0.28 vs. 0.57, 3-7 days postpartum: 0.59 vs. 0.81; P<0.001) and was more likely to report no or slight problems in 4 of 5 health dimensions (mobility, self-care, usual activities, painordiscomfort; P0.04) during interviews 1 and 2. Postpartum QOL converged, but still differed between groups by the time of interview 3 (21-30 days postpartum: 0.85 vs. 0.93; P<0.001). While most women reported no problems by the end of the first postpartum month, the difference in the ability to perform usual activities persisted (P=0.001). In result, fewer QALDs were attained by women in the cesarean section group between day 1 and day 21 postpartum (13.1 vs. 16.6 QALDs; P<0.001). Subgroup analysis showed that having had an episiotomy during vaginal birth was also associated with reduced QOL postpartum, but to a lesser extent than cesarean section. Similar results were obtained when adjusting for socioeconomic, pregnancy and birth characteristics, but postpartum QOL already ceased to be statistically different between groups before interview 3.

    Conclusions: Vaginal births, even with episiotomy, were associated with a higher postpartum QOL than cesarean births among the Indian women in our pilot study. Finding these expected results suggests that the EQ-5D-5L questionnaire is asuitable instrumentto assess postpartum QOL in Indian women.

    Ladda ner fulltext (pdf)
    fulltext
  • 32. Kristianson, L
    et al.
    Lederballe-Pedersen, O
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    The impact of serum uric acid on cardiovascular outcomes in the LIFE study.2004Ingår i: Kidney Interntional, Vol. 65, nr 3, s. 104-109Artikel i tidskrift (Refereegranskat)
  • 33.
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    How common is hypertension - and what do we do about it?2006Ingår i: Journal of Hypertension, Vol. 24, s. 13-Artikel i tidskrift (Övrigt vetenskapligt)
  • 34.
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Valsartan treatment of hypertension - does VALUE add value?2004Ingår i: Lancet, Vol. 3, nr 9426, s. 2010-2011Artikel i tidskrift (Refereegranskat)
  • 35.
    Lindholm, Lars H
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Black, HR
    NYU, Sch Med, New York, NY USA .
    Bakris, GL
    Univ Chicago, Dept Med, Chicago, IL 60637 USA.
    Linas, SL
    Univ Colorado, Hlth Sci Ctr, Denver, CO USA .
    Krum, H
    Monash Ctr Cardiovasc Res & Educ, Melbourne, Vic Australia.
    Weiss, R
    Androscoggin Cardiol Associates, Auburn, AL USA .
    Linseman, JV
    Gilead Colorado Inc, Boulder, CO USA .
    Wiens, BL
    Gilead Colorado Inc, Boulder, CO USA .
    Warren, MS
    Gilead Colorado Inc, Boulder, CO USA .
    Weber, M
    Suny Downstate Med Ctr, Brooklyn, NY 11203 USA .
    Darusentan lowers blood pressure significant on top of multi-drug treatment in patients with resistant hypertension2009Ingår i: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 27, nr Suppl. 4, s. s167-s168Artikel i tidskrift (Refereegranskat)
  • 36.
    Lindholm, Lars H
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Black, HR
    Bakris, GL
    Linas, SL
    Krum, H
    Weiss, R
    Linseman, JV
    Wiens, BL
    Warren, MS
    Weber, M
    Darusentan treatment significantly decreases blood pressure and results in better systolic blood pressure control when added to multi-drug therapy in patients with resistant hypertension2009Ingår i: Journal of Human Hypertension, ISSN 0950-9240, E-ISSN 1476-5527, Vol. 23, nr 10, s. 697-697Artikel i tidskrift (Refereegranskat)
  • 37.
    Lindholm, Lars H
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Carlberg, Bo
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Blood-pressure drugs and cancer: much ado about nothing?2011Ingår i: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 12, nr 1, s. 6-8Artikel i tidskrift (Refereegranskat)
  • 38.
    Lindholm, Lars H.
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Carlberg, Bo
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    The new Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014): a giant undertaking2014Ingår i: Hypertension Research, ISSN 0916-9636, E-ISSN 1348-4214, Vol. 37, nr 4, s. 391-392Artikel i tidskrift (Övrigt vetenskapligt)
  • 39.
    Lindholm, Lars H
    et al.
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Carlberg, Bo
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Medicin.
    Samuelsson, Ola
    Beta blockers in primary hypertension: Do age and type of beta-blocker matter?2006Ingår i: J Hypertens, ISSN 0263-6352, Vol. 24, nr 11, s. 2143-5Artikel i tidskrift (Refereegranskat)
  • 40.
    Lindholm, Lars H
    et al.
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Carlberg, Bo
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Medicin.
    Samuelsson, Ola
    Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.2005Ingår i: Lancet, ISSN 1474-547X, Vol. 366, nr 9496, s. 1545-53Artikel i tidskrift (Refereegranskat)
  • 41.
    Lindholm, Lars H
    et al.
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Kartman, Bernt
    Carlberg, Bo
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Medicin.
    Persson, Mats
    Svensson, Anders
    Samuelsson, Ola
    Cost implications of development of diabetes in the ALPINE study.2006Ingår i: J Hypertens Suppl, ISSN 0952-1178, Vol. 24, nr 1, s. S65-72Artikel i tidskrift (Refereegranskat)
  • 42.
    Lindholm, Lars H
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Mendis, Shanthi
    Prevention of cardiovascular disease in developing countries.2007Ingår i: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 370, nr 9589, s. 720-2Artikel i tidskrift (Refereegranskat)
  • 43.
    Lindholm, Lars H
    et al.
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Samuelsson, A
    Clinical relevance of glucose metabolism disturbances induced by antihypertensive drugs.2004Ingår i: European Heart Journal, Vol. 6, nr suppl, s. 31-35Artikel i tidskrift (Övrigt vetenskapligt)
  • 44.
    Lindholm, Lars H.
    et al.
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Samuelsson, O.
    Carlberg, Bo
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
    Beta-blockers in primary hypertension: No more confusion2006Ingår i: Cardiology at the limits VII / [ed] Lionel H. Opie; Derek M. Yellon, University of Cape Town Press , 2006Kapitel i bok, del av antologi (Övrigt vetenskapligt)
  • 45.
    Lindholm, Lars H
    et al.
    Umeå universitet.
    Spencer, Stuart
    Umeå universitet. The Lancet, London, UK.
    Nationell forskarskola har global räckvidd: både vetenskapligt och geografiskt når doktoranderna långt2014Ingår i: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 111, nr 15, artikel-id CT67Artikel i tidskrift (Övrigt vetenskapligt)
  • 46. Linjer, Erland
    et al.
    Hedner, Thomas
    Jönsson, Bengt
    Ekbom, Tord
    Lindholm, Lars H
    Umeå universitet, Medicinsk fakultet, Folkhälsa och klinisk medicin, Allmänmedicin.
    Dahlöf, Björn
    de Faire, Ulf
    Scherstén, Bengt
    Cost analysis of different pharmacological treatment strategies in elderly hypertensives.2005Ingår i: Blood Pressure, ISSN 0803-7051, Vol. 14, nr 2, s. 107-13Artikel i tidskrift (Refereegranskat)
  • 47.
    MacMahon, Stephen
    et al.
    George Institute for International Health, University of Sydney, Sydney, Australia.
    Alderman, Michael H.
    Albert Einstein College of Medicine, Yeshiva University, New York, USA.
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Liu, Lisheng
    Chinese Academy of Medical Sciences, Fu Wai Hospital, Beijing, China.
    Sanchez, Ramiro A
    Instituto de Cardiologia y Cirugia Cardiovascular, Universidad “Dr René G Favaloro”, Buenos Aires, Argentina.
    Seedat, Yackoob K
    Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa.
    Blood-pressure-related disease is a global health priority.2008Ingår i: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 371, nr 9623, s. 1480-1482Artikel i tidskrift (Refereegranskat)
  • 48.
    Macmahon, Stephen
    et al.
    George Institute for International Health, University of Sydney, Sydney, New South Wales, Australia.
    Alderman, Michael H.
    Albert Einstein College of Medicine, Yeshiva University, New York, New York, USA.
    Lindholm, Lars Hjalmar
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Lisheng, Liu
    Chinese Academy of Medical Sciences, Fu Wai Hospital, Beijing, China.
    Sanchez, Ramiro A.
    Instituto de Cardiologia y Cirugia Cardiovascular, Universidad "Dr René G Favaloro," Buenos Aires, Argentina.
    Seedat, Yackoob K.
    Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa.
    Blood-pressure-related disease is a global health priority2008Ingår i: American Journal of Hypertension, ISSN 0895-7061, E-ISSN 1941-7225, Vol. 21, nr 8, s. 843-844Artikel i tidskrift (Refereegranskat)
  • 49. Mancia, Giuseppe
    et al.
    De Backer, Guy
    Dominiczak, Anna
    Cifkova, Renata
    Fagard, Robert
    Germano, Giuseppe
    Grassi, Guido
    Heagerty, Anthony M
    Kjeldsen, Sverre E
    Laurent, Stephane
    Narkiewicz, Krzysztof
    Ruilope, Luis
    Rynkiewicz, Andrzej
    Schmieder, Roland E
    Boudier, Harry A J Struijker
    Zanchetti, Alberto
    Vahanian, Alec
    Camm, John
    De Caterina, Raffaele
    Dean, Veronica
    Dickstein, Kenneth
    Filippatos, Gerasimos
    Funck-Brentano, Christian
    Hellemans, Irene
    Kristensen, Steen Dalby
    McGregor, Keith
    Sechtem, Udo
    Silber, Sigmund
    Tendera, Michal
    Widimsky, Petr
    Zamorano, José Luis
    Erdine, Serap
    Kiowski, Wolfgang
    Agabiti-Rosei, Enrico
    Ambrosioni, Ettore
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Viigimaa, Margus
    Adamopoulos, Stamatis
    Agabiti-Rosei, Enrico
    Ambrosioni, Ettore
    Bertomeu, Vicente
    Clement, Denis
    Erdine, Serap
    Farsang, Csaba
    Gaita, Dan
    Lip, Gregory
    Mallion, Jean-Michel
    Manolis, Athanasios J
    Nilsson, Peter M
    O'Brien, Eoin
    Ponikowski, Piotr
    Redon, Josep
    Ruschitzka, Frank
    Tamargo, Juan
    van Zwieten, Pieter
    Waeber, Bernard
    Williams, Bryan
    2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).2007Ingår i: Journal of Hypertension, ISSN 0263-6352, E-ISSN 1473-5598, Vol. 25, nr 6, s. 1105-87Artikel i tidskrift (Refereegranskat)
  • 50. Mancia, Giuseppe
    et al.
    De Backer, Guy
    Dominiczak, Anna
    Cifkova, Renata
    Fagard, Robert
    Germano, Giuseppe
    Grassi, Guido
    Heagerty, Anthony M
    Kjeldsen, Sverre E
    Laurent, Stephane
    Narkiewicz, Krzysztof
    Ruilope, Luis
    Rynkiewicz, Andrzej
    Schmieder, Roland E
    Struijker Boudier, Harry A J
    Zanchetti, Alberto
    Vahanian, Alec
    Camm, John
    De Caterina, Raffaele
    Dean, Veronica
    Dickstein, Kenneth
    Filippatos, Gerasimos
    Funck-Brentano, Christian
    Hellemans, Irene
    Kristensen, Steen Dalby
    McGregor, Keith
    Sechtem, Udo
    Silber, Sigmund
    Tendera, Michal
    Widimsky, Petr
    Zamorano, Jose Luis
    Kjeldsen, Sverre E
    Erdine, Serap
    Narkiewicz, Krzysztof
    Kiowski, Wolfgang
    Agabiti-Rosei, Enrico
    Ambrosioni, Ettore
    Cifkova, Renata
    Dominiczak, Anna
    Fagard, Robert
    Heagerty, Anthony M
    Laurent, Stephane
    Lindholm, Lars H
    Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Allmänmedicin.
    Mancia, Giuseppe
    Manolis, Athanasios
    Nilsson, Peter M
    Redon, Josep
    Schmieder, Roland E
    Struijker-Boudier, Harry A J
    Viigimaa, Margus
    Filippatos, Gerasimos
    Adamopoulos, Stamatis
    Agabiti-Rosei, Enrico
    Ambrosioni, Ettore
    Bertomeu, Vicente
    Clement, Denis
    Erdine, Serap
    Farsang, Csaba
    Gaita, Dan
    Kiowski, Wolfgang
    Lip, Gregory
    Mallion, Jean-Michel
    Manolis, Athanasios J
    Nilsson, Peter M
    O'Brien, Eoin
    Ponikowski, Piotr
    Redon, Josep
    Ruschitzka, Frank
    Tamargo, Juan
    van Zwieten, Pieter
    Viigimaa, Margus
    Waeber, Bernard
    Williams, Bryan
    Zamorano, Jose Luis
    2007 Guidelines for the management of arterial hypertension: The task gorce for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)2007Ingår i: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 28, nr 12, s. 1462-536Artikel i tidskrift (Refereegranskat)
12 1 - 50 av 98
RefereraExporteraLänk till träfflistan
Permanent länk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf